top of page

NK-001

PIPELINE

OT-A201

Contact Us

 

Onward Therapeutics SA
Biopôle, bâtiment Serine
Route de la Corniche 8
1066 Epalinges, Switzerland

Onward Therapeutics France SAS

77 rue de Vaugirard

75006 Paris, France

 

contact@onward-therapeutics.com

Content of this website and any communication of Onward Therapeutics has been prepared for general guidance and does not constitute medical advice

 

  • LinkedIn
  • Twitter

Thank you for your message !

PARTNERSHIPS

NEWS & EVENTS

WHO WE ARE

We are a development stage oncology company, focusing on the identification of innovative technologies and the development of truly breakthrough medicines for the treatment of cancer.

 

Our company, led by an experienced team in translational science and drug development, acquires licenses for potential development candidates and invest in partners with transformative technology platforms.

 

We are located at Biopôle, a life sciences campus in Epalinges near Lausanne, Switzerland, we have an affiliate in Paris, France, and also operate from Taipei, Taiwan. 

IDENTIFY promising projects

BUILD partnerships

ADVANCE cancer care

Jul 24, 2023

Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies" 

 

Read More...

Jun 08, 2021

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

 

Read More...

May 04, 2021

Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France

 

Read More...

Feb 17, 2021

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

 

Read More...

Feb 16, 2021

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

 

Read More...

bottom of page